obesity treatment

WHO'S GUIDANCE ON GLP-1 THERAPY FOR OBESITY

The WHO’s first guideline on GLP-1 therapy marks a major shift in treating obesity as a chronic disease rather than a behavioural issue. It conditionally recommends drugs like semaglutide and tirzepatide for adults with obesity, but only alongside diet, exercise, and counselling. While the therapy shows significant weight loss and metabolic benefits, WHO warns of high costs, limited access, safety gaps, and the need for strong health systems to ensure equitable, long-term care.